Market Overview

UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Dropout Assumptions

Related AEGR
Activist Discloses 5.7% Stake In Aegerion Pharmaceuticals
10 Biotech Stories You Might've Missed This Week
Aegerion's Juxtapid Successful in Phase III Japanese Study - Analyst Blog (Zacks)

In a report published Thursday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised the price target from $41.00 to $52.00.

In the report, Karnauskas noted, “AEGR has made assumptions for dropouts, which are key to their guidance of ending the year with 250-300 patients on Juxtapid. While our analysis suggests the co is well on track to beat the guidance, Aegerion wants to be conservative and get more data on dropouts ahead of modifying guidance. Dropout color might come later in the year when the co has more data (too soon for 1Q13 call). While the ph 3 saw 20% drop outs, AEGR expects much lower.”

Aegerion Pharmaceuticals closed on Wednesday at $38.49.

Latest Ratings for AEGR

Oct 2014JefferiesDowngradesBuyHold
Oct 2014JP MorganDowngradesOverweightNeutral
Oct 2014Deutsche BankDowngradesBuyHold

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (AEGR)

Around the Web, We're Loving...